IMVT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMVT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Immunovant's total current liabilities for the quarter that ended in Dec. 2023 was $32.10
The historical data trend for Immunovant's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant Annual Data | |||||||||||
Trend | Dec18 | Mar20 | Mar21 | Mar22 | Mar23 | ||||||
Total Current Liabilities | 0.38 | 15.32 | 18.77 | 44.52 | 43.30 |
Immunovant Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Current Liabilities | Get a 7-Day Free Trial | 41.26 | 43.30 | 51.36 | 40.26 | 32.10 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Immunovant's Total Current Liabilities for the fiscal year that ended in Mar. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 34.594 | + | 1.173 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 7.53 | + | 0 | |
= | 43.30 |
Immunovant's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 24.322 | + | 0.306 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 7.474 | + | 0 | |
= | 32.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Immunovant's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
William L. Macias | officer: Chief Medical Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Eva Renee Barnett | officer: Chief Financial Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Julia G. Butchko | officer: Chief Dev. & Tech. Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Peter Salzmann | director, officer: Chief Executive Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Andrew J. Fromkin | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139 |
George V Migausky | director | C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Mark S. Levine | officer: Chief Legal Officer | 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Jay S Stout | officer: Chief Technology Officer | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Frank Torti | director | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Douglas J. Hughes | director | C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134 |
Rita Jain | officer: Chief Medical Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Michael James Elliott | officer: Chief Scientific Officer | 320 WEST 37TH STREET, NEW YORK NY 10018 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
From GuruFocus
By GuruFocus Research • 11-09-2023
By Marketwired • 09-26-2023
By Marketwired • 09-26-2023
By GuruFocus Research • 01-13-2024
By GuruFocusNews GuruFocusNews • 07-02-2022
By GlobeNewswire • 09-28-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By GuruFocus Research • 10-12-2023
By Marketwired • 10-02-2023
By GuruFocus Research • 10-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.